K. Gregory-Evans Clinic

The Gregory-Evans Clinic specialises in patients with genetic eye disease. Full investigative assessments including DNA testing and medical treatment are undertaken for patients with macular degeneration, retinitis pigmentosa and other diseases of the retina. Genetic counselling work is also undertaken for patients with other genetic eye diseases such as glaucoma and aniridia.

Location: Section E, Eye Care Centre, 2550 Willow Street, Vancouver, Canada. V5Z3N9
Secretary: Yvonne
Current Tel: 778-968-4349
Fax: 604-875-4663
Email: gregoryevanseyes@gmail.com

Pharma-led clinical trials:

2007-2008, Novartis Pharamceuticals
SUSTAIN (Study of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration).

2008-2010, Bayer Schering Pharma
VIEW2 (VEGF trap-eye: investigation of efficiency and safety in wet AMD).

Current clinical trials:


Illustration X. Subretinal neovasularisation complicating a traumatic choroidal rupture. Treatment with ranibizumab Color fundus and fluorescein angiogram images from the left eye at presentation ( A, B, C ) and after three months of treatment ( D, E, F ). B&E : early fluorescein angiogram images; C&F late fluorescein angiograms. Images show marked improvement in clinical appearance and less leakage at three months. (Can J Ophthalmol. 2011;46:337-44).


Illustration Y. Spectral domain, Cirrus-High Definition, optical coherence tomography highlights new features of macular hypoplasia in aniridia. Aniridia patients ( A&B ), with novel PAX6 Q178X nonsense mutations, show loss of the foveal pit and other outer retinal features usually seen in normal adults ( C ). In addition, OCT images from patient B demonstrate a deficiency in the boundary between photoreceptor outer segments and the RPE ( * ) suggestive of phototoxicity( Can J Ophthalmol. 2011;46:337-344).